In an elderly male patient with chronic kidney disease and a parathyroid hormone level of 94 pg/mL, how should his secondary hyperparathyroidism be managed?

Management of PTH 94 pg/mL in Elderly Male with CKD

In an elderly male with CKD and PTH of 94 pg/mL, no specific PTH-lowering treatment is indicated at this time—focus instead on optimizing calcium, phosphate, and vitamin D status while monitoring PTH trends. 1

Rationale for Conservative Approach

Your patient's PTH of 94 pg/mL falls within or near the normal range (typical upper limit ~65-88 pg/mL depending on assay), representing only mild elevation. The 2025 KDIGO Controversies Conference explicitly states that the optimal PTH level in patients with CKD not on dialysis remains undefined, and there is no evidence for a specific PTH target in such patients 1.

Key Management Principles

What warrants action:

• High and progressively increasing PTH levels warrant investigation 1
• Static or slowly rising PTH in this range does not require immediate intervention
• The focus should be on preventing progression rather than treating a single value

Stepwise Management Algorithm

1. Assess and Optimize Foundational Parameters First

Check these labs immediately:

• Serum calcium (corrected for albumin)
• Serum phosphate
• 25-hydroxyvitamin D [25-(OH)D] level

Why this matters: Hypocalcemia stimulates PTH secretion, and hyperphosphatemia increases bone resistance to PTH and correlates with increased PTH levels 1. Correcting these abnormalities may normalize PTH without specific PTH-targeted therapy.

2. Vitamin D Repletion Strategy

If 25-(OH)D is low (<30 ng/mL):

• Supplement with nutritional vitamin D (cholecalciferol or ergocalciferol)
• Target 25-(OH)D ≥30 ng/mL, which may optimize bone health 1
• Do NOT leave vitamin D deficiency untreated, even though large trials haven't shown clinical outcome benefits—these studies weren't designed for vitamin D-deficient populations 1

Avoid activated vitamin D (calcitriol, paricalcitol) at this stage:

• The 2017 KDIGO update recommended against routine use in CKD not on dialysis 1
• PRIMO and OPERA trials showed increased hypercalcemia risk without cardiac benefit 1
• Reserve low-dose active vitamin D only if PTH rises substantially despite optimized nutritional vitamin D and phosphate control 1

3. Phosphate Management

If phosphate is elevated:

• Implement dietary phosphate restriction
• Consider phosphate binders if dietary measures insufficient
• Hyperphosphatemia directly drives PTH secretion and must be controlled before considering PTH-specific therapy 1

4. Monitoring Strategy

Recheck labs in 3 months:

• PTH, calcium, phosphate, 25-(OH)D
• Look for trends, not single values—progressively rising PTH indicates need for escalation 1

What constitutes concerning progression:

• PTH doubling over 6-12 months
• Development of hypocalcemia or hyperphosphatemia
• Symptoms of bone disease (fractures, bone pain)

When to Escalate Treatment

Consider PTH-lowering therapy only if:

• PTH continues rising despite optimized calcium, phosphate, and vitamin D
• PTH reaches levels >2-3 times upper limit of normal (~150-200 pg/mL)
• Patient develops complications (fractures, progressive CKD, cardiovascular events) associated with rising PTH 1

Treatment options at that point:

• Low-dose active vitamin D (calcitriol or alfacalcidol) as supplement to nutritional vitamin D 1
• Calcimimetics (cinacalcet) for more severe cases 2
• Close monitoring for hypercalcemia with either approach

Critical Caveats

The PTH-bone turnover disconnect: PTH levels correlate poorly with actual bone turnover in CKD 1, 3. Some patients have low bone turnover with normal PTH, while others have high turnover with only moderately elevated PTH 1. Your patient's PTH of 94 pg/mL tells you little about actual skeletal health without bone biopsy or turnover markers.

Avoid overtreatment: Suppressed PTH (<150 pg/mL in dialysis patients) associates with worse outcomes 4. While your patient isn't on dialysis, aggressive PTH suppression at this mild elevation could be harmful.

Age considerations: In elderly patients like yours, the risk-benefit ratio favors conservative management given surgical risks 2 and medication side effects (hypercalcemia with vitamin D analogs, hypocalcemia with calcimimetics).